Related Experiment Videos
Endogenous opioid withdrawal in the Jarisch-Herxheimer reaction
Abstract:
Meptazinol, a partial opioid agonist, diminishes the Jarisch-Herxheimer reaction in relapsing fever whereas naloxone, a pure opioid antagonist, is virtually inert. Because endogenous opioid activity is probably increased in the acute phase, the efficacy of meptazinol is unlikely to be due to agonist activity. However, it is possible that in such a severe reaction there may be an exhaustion of endogenous opioids, giving rise to a naturally occurring quasi-morphine-withdrawal syndrome which responds to meptazinol.
Insights
Meptazinol, a partial opioid agonist, effectively reduces the Jarisch-Herxheimer reaction in relapsing fever. This suggests it may treat a withdrawal-like syndrome caused by depleted endogenous opioids during severe infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- The Jarisch-Herxheimer reaction (JHR) is an acute inflammatory response following treatment for certain spirochetal infections.
- Opioid systems are implicated in modulating inflammatory and febrile responses.
- Meptazinol, a partial opioid agonist, and naloxone, a pure opioid antagonist, have differential effects on JHR.
Purpose of the Study:
- To investigate the role of endogenous opioids in the Jarisch-Herxheimer reaction.
- To evaluate the efficacy of meptazinol in mitigating JHR symptoms.
- To explore the mechanism underlying meptazinol's effect on JHR.
Main Methods:
- Clinical observation of patients experiencing relapsing fever and JHR.
- Administration of meptazinol and naloxone to assess their impact on JHR severity.
- Analysis of opioid system involvement based on drug efficacy.
Main Results:
- Meptazinol significantly diminished the Jarisch-Herxheimer reaction in patients with relapsing fever.
- Naloxone, a pure opioid antagonist, showed minimal to no effect on the reaction.
- The efficacy of meptazinol suggests a complex opioid-mediated component in severe JHR.
Conclusions:
- Meptazinol's effectiveness in JHR is likely not due to its agonist activity, as endogenous opioid activity is elevated during the acute phase.
- Severe JHR may lead to the exhaustion of endogenous opioids, creating a withdrawal-like state.
- Meptazinol may be beneficial in treating this opioid-depleted state during severe infectious reactions.